about
Mechanism-Oriented Therapy of Irritable Bowel SyndromeOverlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye?Inflammation in irritable bowel syndrome: Myth or new treatment target?Irritable bowel syndrome and inflammatory bowel disease overlap syndrome: pieces of the puzzle are falling into placeReview article: biomarkers and personalised therapy in functional lower gastrointestinal disorders.Neurobiological Mechanism of Acupuncture for Relieving Visceral Pain of Gastrointestinal Origin.Does calprotectin level identify a subgroup among patients suffering from irritable bowel syndrome? Results of a prospective study.Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology.Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence.Biomarkers as a diagnostic tool for irritable bowel syndrome: where are we?Immune response in irritable bowel syndrome: A systematic review of systemic and mucosal inflammatory mediators.Neuroimmune factors in functional gastrointestinal disorders: A focus on irritable bowel syndrome.New Pathways, New Targets: Visceral Hypersensitivity Pathogenesis in Irritable Bowel Syndrome.Global Cytokine Profiles and Association With Clinical Characteristics in Patients With Irritable Bowel Syndrome.New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond.Increased intestinal mucosal leptin levels in patients with diarrhea-predominant irritable bowel syndrome.Editorial: mesalazine to prevent recurrent acute diverticulitis-the final nail in the coffin.Editorial: diet, inflammation and irritable bowel syndrome.Current insights into the innate immune system dysfunction in irritable bowel syndrome.Efficacy of mesalazine in IBS.Cytokine Profile and Immunoglobulin E-mediated Serological Food Hypersensitivity in Patients With Irritable Bowel Syndrome With Diarrhea.Irritable bowel syndrome
P2860
Q26747875-19AB3829-7BBD-47E1-B1A8-9F344ED4FCEDQ26765219-E5AA1BD4-713A-4C25-8650-CE451BE744A9Q26768545-62ADE717-11B2-457D-8A2E-5F6C34EC130AQ28071496-12C33E96-C576-4E95-ADDA-050C17B494A3Q36021269-078E6994-5324-4E5B-A6E8-EB5EC18098A0Q37627512-CD5DF534-5966-4671-BFF1-1B461AD61E1BQ37698552-7378AB0E-BBB8-4C91-86E8-5116B7F194EFQ38445280-FEEA6231-E522-4082-B999-3AAB55E127D8Q38764554-D6FB831A-2B24-409C-8A40-9EDD49505DF3Q38765085-BD5F89A4-B9F7-4048-8D64-A061C22F0E9AQ38899859-AF3DB7AF-F783-4CF2-8923-6B3F9B2DEC3AQ39058964-1F126B6D-F83A-42B8-8478-2C38625FC8EEQ39776902-15D697D0-9347-4194-9CD1-8D80ED27C18EQ40642008-B0798E0E-6BBD-4FB5-A341-980B8D9021E8Q42695148-09DAA9DD-C355-473F-B049-5D2554C89026Q47649402-D081FD9B-6870-4872-8AE1-F5DF6072219CQ48125479-7A41E08A-DD29-4207-9C7D-EA4CD1EB2D4FQ48334666-FDCCB002-E044-48B7-88F2-D61B69F43467Q52673108-5BC3C9FB-BF99-4770-8F87-0E051967AFBFQ52837356-75FE383F-8C8B-457C-B6D7-DDAFDE0639C6Q55624674-AF99F759-7334-46C5-967C-F04B7B021355Q56965677-E3B4E13B-3597-4224-BE54-280D44840DDF
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Randomised controlled trial of mesalazine in IBS.
@ast
Randomised controlled trial of mesalazine in IBS.
@en
type
label
Randomised controlled trial of mesalazine in IBS.
@ast
Randomised controlled trial of mesalazine in IBS.
@en
prefLabel
Randomised controlled trial of mesalazine in IBS.
@ast
Randomised controlled trial of mesalazine in IBS.
@en
P2093
P2860
P50
P1433
P1476
Randomised controlled trial of mesalazine in IBS.
@en
P2093
Alfredo Saggioro
Antonio Benedetti
Bastianello Germanà
Cesare Cremon
Franco Bazzoli
Giorgio Zoli
Giovanni Barbara
Guido Basilisco
Luigi Benini
Marcello Rodi
P2860
P356
10.1136/GUTJNL-2014-308188
P407
P577
2014-12-01T00:00:00Z